Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT06538311
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Alzheimer Disease
  • Amnestic Symptoms
  • Logopenic Progressive Aphasia
  • Mild Cognitive Impairment

Eligibility Criteria

Sex
ALL
Age
40 Years - 99 Years
Healthy Volunteers
Accepted

Interventions

  • Active rTMS — DEVICE
    All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
  • Sham rTMS — DEVICE
    All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).

Study Details

In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI). This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI). Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.

Key Dates

Start date
May 1, 2023
Status verified
Feb 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: AD, aMCI, lvPPA patients, and preclinical AD
    All participants will receive the same study interventions in a within-subject crossover design.

Primary Outcome Measure

Changes in Memory [ Time Frame: Baseline and post-treatment Day 11 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02129
Alexandra Touroutoglou, PhD
[email protected]
Alexandra Touroutoglou, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Massachusetts General Hospital· Boston, MA

Related Studies